MedTrace Logo

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

NCT01795313 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-02-05

No results posted yet for this study

Summary

The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.

Conditions

Interventions

BIOLOGICAL

HLA-A2 restricted synthetic tumor antigen

DRUG

Imiquimod

OTHER

enzyme-linked immunosorbent assay

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Solving Kids' Cancer

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • James Felker

    lead OTHER

Principal Investigators

  • James Felker, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2025-12-03
Completion
2025-12-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01795313 on ClinicalTrials.gov